{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:30Z","timestamp":1761513330951},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11102-013-0503-3","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T12:58:20Z","timestamp":1376398700000},"page":"320-326","source":"Crossref","is-referenced-by-count":42,"title":["Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, Phase II study"],"prefix":"10.1007","volume":"17","author":[{"given":"M.","family":"Boscaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Findling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schopohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,14]]},"reference":[{"key":"503_CR1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"503_CR2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing\u2019s disease over 50\u00a0years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632\u2013642","journal-title":"J Clin Endocrinol Metab"},{"key":"503_CR3","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1\u00a0year after disease remission. J Clin Endocrinol Metab 88:2527\u20132533","journal-title":"J Clin Endocrinol Metab"},{"key":"503_CR4","first-page":"137","volume":"65","author":"AW Eerden van der","year":"2007","unstructured":"van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR (2007) Cushing\u2019s syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 65:137\u2013141","journal-title":"Neth J Med"},{"key":"503_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ecl.2007.10.004","volume":"37","author":"AA Toogood","year":"2008","unstructured":"Toogood AA, Stewart PM (2008) Hypopituitarism: clinical features, diagnosis, and management. Endocrinol Metab Clin North Am 37:235\u2013261","journal-title":"Endocrinol Metab Clin North Am"},{"key":"503_CR6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-10-10","volume":"10","author":"BM Biller","year":"2010","unstructured":"Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing\u2019s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10","journal-title":"BMC Endocr Disord"},{"key":"503_CR7","unstructured":"Novartis Pharmaceuticals (2012) Signifor prescribing information. Available at: http:\/\/www.pharma.us.novartis.com\/cs\/www.pharma.us.novartis.com\/product\/pi\/pdf\/signifor.pdf . Last accessed Feb 2013"},{"key":"503_CR8","unstructured":"Corcept Therapeutics (2012) Korlym prescribing information. Available at: http:\/\/www.corcept.com\/prescribinginfo.pdf . Last accessed Feb 2013"},{"key":"503_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707\u2013716","journal-title":"Eur J Endocrinol"},{"key":"503_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28\u201347","journal-title":"Endocr Rev"},{"key":"503_CR11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary dependent Cushing\u2019s disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122","journal-title":"J Clin Endocrinol Metab"},{"key":"503_CR12","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"503_CR13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BMK (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924","journal-title":"N Engl J Med"},{"key":"503_CR14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMc1204078","volume":"366","author":"R Libe","year":"2012","unstructured":"Libe R, Groussin L, Bertherat J (2012) Pasireotide in Cushing\u2019s disease. N Engl J Med 366:2134\u20132135","journal-title":"N Engl J Med"},{"key":"503_CR15","unstructured":"Pivonello R, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, on behalf of the Pasireotide B2305 Study Group (2011) Improvement in clinical signs and symptoms of Cushing\u2019s disease following 12\u00a0months\u2019 pasireotide therapy. Endocrine Abstracts 26:abst P284"},{"key":"503_CR16","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/jc.2003-030110","volume":"88","author":"R Cozzi","year":"2003","unstructured":"Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090\u20133098","journal-title":"J Clin Endocrinol Metab"},{"key":"503_CR17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, Chang T-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR\u00ae (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859\u2013868","journal-title":"Clin Endocrinol (Oxf)"},{"key":"503_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","volume":"13","author":"S Melmed","year":"2010","unstructured":"Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel\u00ae therapy: a randomized, placebo-controlled, multicenter study with a 52\u00a0week open extension. Pituitary 13:18\u201328","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"503_CR19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","volume":"92","author":"R Pivonello","year":"2010","unstructured":"Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A (2010) Pathophysiology of diabetes mellitus in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):77\u201381","journal-title":"Neuroendocrinology"},{"key":"503_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167:311\u2013326","journal-title":"Eur J Endocrinol"},{"key":"503_CR21","doi-asserted-by":"crossref","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2013) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary. doi: 10.1007\/s11102-013-0483-3 [Epub ahead of print]","DOI":"10.1007\/s11102-013-0483-3"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-013-0503-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0503-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T23:14:41Z","timestamp":1553642081000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-013-0503-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,14]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s11102-013-0503-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,14]]}}}